Concerning the Significance of Paraoxonase-1 and SR-B1 Genes in Atherosclerosis
Francisco Rodríguez Esparragón, a Yaridé Hernández Trujillo, a Antonio Macías Reyes, a Enrique Hernández Ortega, a Alfonso Medina, b and José C. Rodríguez Pérez a,c

a Unidad de Investigación, Hospital Universitario de Gran Canaria Doctor Negrín, Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.

b Servicio de Cardiología, Hospital Universitario de Gran Canaria Doctor Negrín, Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.

Sobre los genes paraoxonasa-1 y SR-B1, y su importancia en la aterosclerosis

La lipoproteína de alta densidad (HDL) constituye un factor de protección independiente de enfermedad cardiovascular. La enzima paraoxonasa-1 (PON-1) contribuye a las propiedades antiaterogénicas asociadas al HDL. Estudios in vitro muestran que posee una gran heterogeneidad de sustratos, algunos de los cuales participan en la progresión de las lesiones ateroscleróticas. Se han desarrollado modelos animales que muestran su papel ateroprotector. En humanos, las variantes PON-1 Gln192Arg y Met55Leu parecen asociarse con una mayor susceptibilidad cardiovascular, con diferentes actividades y concentración de la proteína PON-1. El gen CLA-1 constituye el primer receptor de alta afinidad de HDL bien caracterizado. El receptor CLA-1 participa en el transporte reverso de colesterol a través de la entrada selectiva de ésteres de colesterol nativos y oxidados, y su papel ateroprotector se ha deducido de los estudios en animales genéticamente manipulados. En humanos, el gen CLA-1 es polimórfico y algunas de sus variantes han sido previamente asociadas con cambios fenotípicos en lipoproteínas plasmáticas. Ambos genes participan en el complejo metabolismo del HDL, y, presumiblemente, en los mecanismos de defensa frente a estrés oxidativo.


INTRODUCTION

According to the oxidation hypothesis of atherogenesis, increased generation of free radicals and reactive oxygen species, possibly associated with weakened antioxidant defense mechanisms, is responsible for atherosclerosis. Oxidized low-density lipoprotein (LDL) is an independent protective factor against cardiovascular disease. The enzyme paraoxonase-1 (PON-1) contributes to the antiatherogenic effects of HDL. In vitro studies have demonstrated that paraoxonase’s substrates are highly heterogeneous and that some contribute to the development of atherosclerotic lesions. The atheroprotective role of PON-1 was established in genetically engineered animal models. In humans, the PON-1 Gln192Arg and Met55Leu polymorphisms appear to be associated with increased susceptibility to cardiovascular disease and with different PON-1 activity levels and concentrations. The CLA-1 (CD36 and Lysosomal integral membrane protein-II Analogous-1) gene is the human homologue of the murine SR-B1 (Scavenger Receptor class B type 1) gene. SR-B1 was the first high-affinity HDL receptor to be identified at the molecular level. The CLA-1 receptor plays a pivotal role in HDL-mediated reverse cholesterol transport by mediating the selective uptake of free cholesterol as well as of native and oxidized cholesteryl esters. Its atheroprotective role has also been established in transgenic mouse studies. Several polymorphic variants of the CLA-1 gene have been described, some of which are associated with phenotypic changes in plasma lipoproteins. Both genes participate in the complex HDL metabolic pathway and, presumably, also in defense mechanisms against oxidative stress.

lipoproteins (LDL) and derivative products generated in association with these oxidative processes can accumulate in the arterial wall and accelerate the atherosclerotic process. In principle, any enzymatic system that generates free radicals could be implicated in the oxidation of LDL particles, for example, the NADPH oxidase system, the myeloperoxidase system, the P450 system, the mitochondrial electron transport chain, and the lipooxygenase system. The importance of lipooxygenase was first investigated in studies carried out in vitro, although several in vivo studies have since corroborated the in vitro findings. The role of lipooxygenase has been further confirmed by experiments with apolipoprotein E and 12/15-lipoxygenase double knockout mice, in which atherosclerotic lesions decreased substantially, although contradictory findings have been reported.

**Seeding Mechanism**

The action of 15- and 12-lipoxygenases on arachidonic and linoleic acid generates mainly hydroperoxyeicosatetraenoic acid (HPETE) and hydroperoxyoctadecatetraenoic acid (HPETE). Several experimental findings support, at least partially, a mechanism of formation of mildly oxidized LDL, whereby phospholipids derived from arachidonic acid are oxidized and these metabolic products of lipooxygenases, particularly HPETE and HPETE, are taken up by different LDL lipids. However, LDL particles also need to be seeded with reactive oxygen species for extensive oxidation to occur. High-density lipoproteins (HDL) and their main structural component, apolipoprotein A1, can prevent oxidation of LDL. A number of molecular mechanisms may arise after transfer of cholesterol ester hydroperoxides (CEOOH) from LDL to HDL, in a process partially determined by the enzymatic activity of the cholesterol ester transfer protein (CETP). Nevertheless, the role of CETP is potentially atherogenic and CETP inhibitors, have been shown to afford protection in several clinical trials. It should, however, be remembered that the mechanism of cholesterol ester transfer from HDL to apolipoprotein B lipoproteins (in a process that leads to the exchange of triglycerides), operates both ways and depends on the concentration of triglyceride-rich lipoproteins. The renovation of HDL rather than a high concentration of HDL is thought to be most relevant to vascular protection. In particular, the action of CETP in HDL facilitates esterification by lecithin-cholesterol acyltransferase (LCAT) and therefore, the efflux of cholesterol. In turn, the combined action of CETP and hepatic lipase on mature HDL (HDL2) generates HDL fractions that contain lower concentrations of lipids and that are better cholesterol acceptors.

The mechanism of formation of mildly oxidized LDL comprises at least 3 steps. The first consists of the aforementioned seeding of LDL particles with the metabolic products of arachidonic acid and with CEOOH. In the second step, LDL crosses the subendothelial space, where there is an additional accumulation of reactive oxygen species. The third step involves oxidation of LDL phospholipids on reaching a threshold concentration of reactive oxygen species. The enzymatic activity of paraoxonase presumably intervenes in the first of these steps. The mechanisms covered by this review are represented schematically in Figure 1.

**Measuring Oxidized Phospholipids and Hydroperoxides in Plasma**

The method used for measuring lipid hydroperoxides in plasma depends on whether total concentrations or concentrations in subfractions are determined. The wide variety of techniques used has led to discrepancies in the measurement of the normal content of peroxides in healthy subjects. Bowry et al. using high performance liquid chromatography with chemoluminescence detection, found that HDL in both plasma and isolated lipoproteins (HDL and LDL) carried 85% of the total content of CEOOH and phospholipid hydroperoxides, detected as hydroperoxides of phosphatidylcholine. In contrast, Nourooz-Zadeh et al. analyzed the total content of lipid hydroperoxides and found that they resided mainly in LDL particles and not in HDL ones.

**Paraoxonases 1, 2, and 3 (PON-1, PON-2, and PON-3)**

Human paraoxonase/arylesterase (PON-1) (EC 3.1.1.2) is a calcium-dependent glycoprotein that is present bound to HDL particles. Investigators have attempted to demonstrate that serum paraoxonase decreases the risk of coronary artery disease by destroying proinflammatory molecules involved in the initiation and progression of atherosclerotic lesions. The antiatherogenic potential of paraoxonase is derived from its capacity to hydrolyze oxidized lipids, phospholipids, and CEOOH, thus preventing them from accumulating in LDL particles. In vitro studies have shown that paraoxonase activity prevents oxidation of LDL particles and even oxidation of the HDL particles themselves. PON-1 can act in a similar fashion in vivo, and PON-1 is also characterized by hydrolyzing different carboxylic acid esters and some organophosphates. Although the actual physiological substrate of the PON-1 enzyme is not well known, it has been possible to determine its serum activity using paraoxon as a substrate. Determination of this activity has shown that serum levels of paraoxonase vary from individual to individual but remain relatively constant in...
A range of physiopathological situations linked to increased oxidative stress and environmental factors can lower serum paraoxonase activity. Moreover, increased oxidative stress has been reported in PON1 knockout mice and in apo E/PON1 double-knockout mice—models in which a different response to macrophage expression of PON2 and PON3 was reported.

Binding between paraoxonase and HDL particles may explain the inverse relationship between HDL levels and coronary artery disease reported in a number of population studies. The antioxidant activity could be responsible for the protective role of paraoxonase. Such activity would be conserved even in the process of reverse cholesterol transport. Thus, esterification of excess cholesterol occurs on the surface of the HDL particles and is mediated by LACT activity, which is particularly sensitive to lipid hydroperoxides. It is important to remember that the enzymatic activity of paraoxonase is limited to certain subfractions of HDL and that apolipoprotein A1 is required to stabilize the enzyme.

The human gene PON1 maps to the long arm of chromosome 7 (7q21-q22) and exhibits interesting polymorphisms. The Gln192 Arg (Q/R) polymorphism is responsible for the PON1 A (Q) and PON1 B (R) alleles, which are associated with different levels of enzymatic activity according to the substrate. The Met55 Leu polymorphism is responsible for the appearance of the L (55 leucine) and M (55 methionine) alleles. The Met55 Leu variant is the one that modifies serum concentrations, but not the enzymatic activity of paraoxonase. The Gln192 Arg polymorphism of the PON1 gene has been associated with vascular disease in diabetic subjects and nondiabetic subjects. However, not all groups have found such an association. Some meta-analyses have been published that show a weak association between this variant and cardiovascular disease. Although other nongenetic determinants are partly responsible for interindividual variability of PON1 activity, some authors think it appropriate to consider genotypes and PON1 activity together in studies of association.

Moreover, the fact that the association does not appear in all populations studied suggests that the variant does not correspond to a functional mutation but is rather a marker of another mutation in the PON1 gene itself or another nearby gene. There may also be interactions between the genotype and environment that have yet to be well characterized or that have a low prevalence in certain populations but that would be important for these studies.

The possibility that the Met55 Leu polymorphism is a genetic risk factor for cardiovascular disease was assessed by Garin et al., who found that Leu55 homozygosis was an independent risk factor for cardiovascular disease in subjects with diabetes. The mechanism by which PON1 polymorphisms increase susceptibility to cardiovascular disease is not known. The presence of the R192 and L55 alleles suggests greater paraoxonase activity towards paraoxon, although these alleles are variants associated with risk in certain populations. This posed an important dilemma for sometime because hydrolysis activity against paraoxon was linked to activity against the real enzyme substrate. Certain theories were put forward to...
explain this paradox. Reduced paraoxonase enzymatic activity after myocardial infarction, in familial hypercholesterolemia, in diabetes, and in association with renal failure suggested a direct influence of oxidative stress on the modulation of activity and enzyme concentration (Figure 2). On the other hand, greater hydrolytic activity against paraoxon or other exogenous substrates would not necessarily imply, as had been suggested, a greater antioxidative capacity. This latter insight contributed to the corresponding experimental confirmation in humans. Mackness et al found that the capacity of HDL particles to protect against LDL oxidation was greater for the QQ/MM homozygotes than for the RR/LL homozygotes (Figure 3). Cao et al observed that the differences in paraoxon hydrolysis resulting from the Gln192Arg variant did not affect the capacity of the PON-1 protein to protect against oxidation of LDL particles. Aviram et al observed that deactivating the (calcium-dependent) PON-1 arylesterase activity did not suppress the capacity of the enzyme to inhibit LDL oxidation. In contrast, inhibitory activity could be suppressed by heating. These authors suggested that different active sites of PON-1, one corresponding to calcium-dependent paraoxonase activity, the other to calcium-independent activity, were responsible for protection against LDL oxidation.

After the initial characterization of the PON1 gene, new PON-like genes, PON2 and PON3, were identified, also mapping to 7q21.3. Unlike PON1, which is mainly expressed in the liver, PON2 is expressed in a variety of tissues. Mochizuki et al identified several forms of mRNA from the PON2 gene produced by alternative splicing or by use of a second transcription start site. Likewise, these authors characterized 2 polymorphisms in the gene coding sequence: Arg148Gly and Cys311Ser. Sanghera et al observed that PON1 (Gln192Arg) and PON2 (Cys311Ser) polymorphisms both
contributed synergistically to cardiovascular risk in Asian Indians.

As discussed earlier, the paraoxonase gene family comprises 3 members: PON1, PON2, and PON3. The physiological role of the corresponding gene products is of increasing interest. So far, the serum paraoxonase/arylesterase PON-1 and the paraoxonase PON-3 from rabbit serum have been characterized.36 Unlike PON-1, PON-3 presents only limited arylesterase activity and complete lack of paraoxonase activity; however, it rapidly hydrolyzes lactones and its protective activity against Cu
2+—induced oxidation of LDL particles is greater than that reported for the PON-1 protein.

Which Enzyme Is Mostly Responsible for the Antioxidant Activity of HDL Particles?

The paraoxonase enzyme is not the only one that affords HDL particles protection against oxidation; other enzymes are implicated. The most important of these is platelet-activating factor acetylhydrolase (PAF-AH). Plasma PAF-AH enzymatic activity is responsible for deactivation of platelet-activating factor (PAF), thereby regulating its function and pathophysiological effects.37 Approximately 70% of the plasma activity of PAF-AH is associated with LDL particles and the rests with HDL particles, suggesting an active exchange between the 2 fractions.38 Lipid peroxides are hydrolyzed by PAF-AH, which acts like phospholipase A2 but not like phospholipase C or D, and its antiatherogenic role is strongly debated.39,40 Marathe et al41 published an excellent study that suggested that PAF-AH and not the enzymatic activity of paraoxonase is responsible for all hydrolysis activity of oxidized phospholipids. As discussed earlier, PON-1 is a calcium-dependent enzyme, whereas PAF-AH is not calcium dependent. PAF-AH is a phospholipase A2 that belongs to the serine-esterase family and, as such, its activity can be inhibited by specific inhibitors that block PAF-AH activity but not PON activity. In fact, paraoxonase lacks serine residues at its active site. With this strategy, it has been shown that PAF-AH is the only HDL phospholipase A2 and that PON-1 lacks phospholipase activity against PAF or oxidized phospholipids. Nevertheless, direct evidence suggests that PON-1 should at least be present for antioxidant and antatherogenic effects to occur.42,43 Some authors have confirmed the PAF hydrolytic activity of serum PON-1 by using specific inhibitors of PAF-AH activity.44 In addition, in the knockout mouse model for the PON1 gene, PAF-AH activity is similar to that of the wild type.45,46 The HDLipoprotein isolated from PON1 knockout mice is proinflammatory, that is, in absence of PON-1, PAF-AH activity is unable to maintain the antioxidant properties of the HDL particles.27,28 In transgenic animals that express human PON1, a certain degree of protection has been found against the development of atherosclerosis.27,47 Such protection has also been found in murine models that overexpress PAF-AH.47,48 Alternatively, coordinated action of both enzymes has been suggested in vivo, as their affinity for oxidized phospholipids varies according to the length of the esterified fatty acid chain at the sn-2 position.49,50-52 These excellent studies complete those done by Aviram et al50,53 and Rozenberg et al,54,55 who observed differential hydrolysis of oxidized lipids both in vitro and in atherosclerotic lesions using Q and R recombinant isozymes. Thus, the Q isoform lowered Cu
2+—induced oxidation of the LDL particles by 33% compared to 20% for the R isoform. These latter studies focussed on developing methods to provide increasingly pure paraoxonase proteins, and so managed to show that the protein by itself seems unable to prevent oxidation of LDL particles.56-57 Recently, studies have been published of other molecular mechanisms that involve the interaction between HDL and paraoxonase and so may mediate vascular protection.58,59

Thiolactone Hydrolase Activity

Homocysteine (Hcy) measured as total plasma homocysteine (tHcy) is considered as an independent and graded risk factor for cardiovascular disease.60,61 The determinants of changes in tHcy plasma concentration are by-and-large known and include both environmental and genetic factors.62-64 The molecular hypotheses that link elevated Hcy concentrations with the disease include direct toxicity towards endothelial cells, oxidation of Hcy, smooth muscle cell growth, and activation of genes important in the development of atherosclerosis.65-67 Elevated Hcy in plasma is associated with other processes related to proteins. Between 80% and 90% of plasma Hcy is bound to proteins, approximately half this concentration of methionine, and that this formation is directly proportional to the concentration of this lactone.68-70 In vitro studies have shown that the formation of this lactone is directly proportional to the concentration of Hcy and inversely proportional to the concentration of methionine, and that this formation is inhibited by administration of folic acid.71,72 If most Hcy is bound into proteins and there is also mechanism that can edit Hcy, the next question would be whether the incorporation of Hcy to proteins happens during or after translation. Evidence from in vitro studies done with certain cell types shows that this incorporation occurs after translation.73 This is particularly important because in vitro studies have shown that N-homocysteinylation of proteins may be mediated by metabolic conversion of Hcy into its corresponding lactone in certain physiological situations. Detoxification
of homocysteine thiolactone therefore constitutes a crucial mechanism. Different studies have shown hydrolysis of these lactones is one of the functions of the paraoxonase enzyme. The molecular identity has also been revealed. Is this hydrolytic activity against homocysteine thiolactone the main role of PON-1?

**Thiolactone Hydrolase Activity and Paraoxonase Isoforms**

Jakubowski et al. showed that the hydrolysis activity of homocysteine thiolactone differs according to PON1 genotype. High thiolactonase activity was found in carriers of the R192 and L55 alleles, whereas activity was lower in carriers of the Q192 and M55 alleles. The authors suggest that low lactonase activity could be an important cardiovascular risk factor in subjects with high plasma concentrations of Hcy, an explanation supported by some studies. According to Billecke et al., the Q and R isoforms show variable specificity towards different lactones and also towards different carboxylic acid esters. This would certainly explain previous clinical observations on the differential pharmacological effects of lipid-lowering drugs on serum paraoxonase activity.

**The SR-B1 (CLA1) Gene**

The metabolism of the HDL particles involves a selective cell uptake process such that HDL components enter the cholesterol ester but not the protein fraction. This selective uptake process is mediated in mouse by the scavenger receptor class B type 1 or SR-B1. The new gene was denominated CLA1 (CD36 and LIMPII analogue 1). Murao et al. confirmed that the SR-B1 sequence was 81% identical with the CLA1 sequence. Alternative splicing of the CLA1 gene produces 2 forms, giving rise to 2 messengers from which 2 proteins of 409 and 509 amino acids have been deduced. The form identified by Murao et al. similar to SR-B1, corresponds to the 509-amino-acid protein. Acton et al. have identified several polymorphisms of the sequence of the human CLA1 gene in a healthy control population. The authors characterized intron variants (introns 3 and 5) and exon variants (exons 1, 8 and 11) by single-chain conformational analysis and sequencing. Two findings are, in our opinion, particularly interesting. The Gly→Ser substitution located in the second coded amino acid in the cDNA molecule (G/A substitution in the first triplet base) has already been associated with higher plasma concentrations of HDL and lower concentrations of LDL in men. On the other hand, the C→T substitution, located in the third base of codon 350 of the cDNA molecule, is associated with lower concentrations of LDL in women.

**CLA1 (SR-B1) and Antioxidant Properties of HDL**

There are several mechanisms responsible for the antiatherogenic effects of HDL particles. The most important is reverse cholesterol transport, a mechanism by which HDL particles take up excess cholesterol from extrahepatic tissues. Cholesterol is esterified through LCAT action then selectively transported to the liver, where CLA-1 mediated entry into the cholesterol ester occurs (Figure 1). Uptake of cholesterol ester by the liver is coupled with the synthesis and secretion of bile acids. The importance of the antiatherogenic

---

**Figure 4. A: Mean concentration of total plasma homocysteine (Hcy) according to the PON1 genotypes Gln192Arg RR (Arg/Arg); QR (Gln/Arg); QQ (Gln/Gln) in a control group of 243 healthy men not receiving pharmacological treatment.**

**B: Mean concentration of total plasma homocysteine according to the PON1 genotype Gln192Arg in a group of 20 patients treated with statins.**
According to experiments with SR-BI and LCAT knockout murine models, the metabolism of HDL particles poses a fundamental question. It is necessary to determine whether hepatic expression of SR-B1 favors atherogenesis when HDL concentrations are reduced, or whether antiatherogenic actions occur on elimination of cholesterol ester. The findings presented earlier reveal a fundamental antiatherogenic role. This is because expression occurs mainly in the liver, where its activity as a scavenger receptor would be important. Furthermore, regulation appears different, at least in macrophages and in Kupffer cells. Some regulation mechanisms are subtle. Thus, HDL particles themselves regulate the expression of SR-B1 in macrophages. Particles of HDL induce activation of PPAR-gamma (messenger and protein) and its translocation to the nucleus, but they also induce phosphorylation of PPAR-gamma mediated by MAP-kinases, so preventing expression of the response genes (SR-B1 and CD36 among others) and thereby suggesting a mechanism by which HDL particles inhibit lipid accumulation.

**CLA-1 (SR-B1), PON-1, and Lipid Oxidation: Hypothesis**

Navah et al.1-3 presented experimental evidence to support the LDL seeding mechanism. Their work and other experiments also showed that the action of normal HDL particles on LDL particles effectively deactivates the atherogenic load of the LDL particles. It has also been shown that reverse transport processes participate in the elimination of this atherogenic load. Moreover, reverse transport of lipid hydroperoxides, in particular, CEOOH is, as mentioned earlier, much more effective than that of native phospholipids and cholesterol esters.4,5 It would therefore follow that the PON-1 enzymatic activity for elimination of lipid hydroperoxides and CEOOH and their elimination by reverse cholesterol transport would contribute synergistically to the decrease in cardiovascular risk.

We attempted to address this question through analysis of polymorphic alleles described for the CLA1 gene (exons 1 and 8 and intron 5) by assigning them a measurable phenotype and determining an associated cardiovascular risk. Then, in a second phase, we assessed whether any association had occurred with some of the allelic variants described for the PON1 gene. We were able to confirm the presence of this genetic synergy. We also found that some of the allelic variants of CLA-1 modulated the plasma content of CEOOH. However, we did not obtain similar phenotypic evidence associated with PON1 polymorphisms.

**CONCLUSIONS**

An atheroprotective role linked to reverse transport should be considered in addition to the antioxidative effect of different enzymes associated with HDL particles. The identification of multiple substrates for the paraoxonase-1 enzyme has extended the perspective of vascular protection mediated by HDL particles, although the exact molecular mechanisms by which this occurs have yet to be identified. The characterization of the CLA-1 receptor, its function, and its possible role as a determinant of the variation of plasma concentrations of oxidized lipids contributes to the knowledge of HDL metabolism and suggests the need for more comprehensive approaches in human studies, as well as the possibility of new therapeutic targets.

**ACKNOWLEDGMENTS**

The authors thank the work done by the technician Ms. Lidia Estupiñán-Quintana.

**REFERENCES**


Rodríguez Esparragón F et al. Concerning the Significance of Paraoxonase-1 and SR-B1 Genes in Atherosclerosis

42. Adkins S, Gan KN, Mody M, Da Lu DN. Molecular basis for the formation of human serum paraoxonase/arylesterase: photolabile or antigen at position 191, for the respective A or B alleles. Am J Hum Genet. 1993;52:598-608.


Genes in Atherosclerosis

77. Nygard O, Vollset SE, Refsum H, Brattstrom L, Ueland PM. 
76. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, 
75. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Up- 
74. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler 
73. Ribas V, Sanchez-Quesada JL, Anton R, Camacho M, Julve J, 
72. Rosenblat M, Vaya J, Shih D, Aviram M. Paraoxonase 1 
71. Teiber JF, Draganov DI, la Du BN. Purified human serum 
70. Rozenberg O, Shih DM, Aviram M. Human serum paraoxona-
69. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Ro-
68. Stanger O, Weger M. Interactions of homocysteine, nitric oxide,
67. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, 
66. Cortese C, Motti C. MTHFR gene polymorphism, homocystein-
65. Acton SL, Scherer PE, Lodish HF, Krieger M. Expression clo-
64. Tomas M, Sentí M, Gascón-Farías V, Vila J, Torrents A, Covas 
63. Jakubowski H. Molecular basis of homocysteine toxicity in hu-
62. Calvo D, Vega MA. Identification, primary structure, and distri-
61. Davignon J, Jacob RF, Mason RP. The antioxidant effects of 
60. Jakubowski H. Translational accuracy of aminoacyl-tRNA syn-
59. Clarkson DW. Relative roles of albumin and ceruloplasmin as 
58. Nyydijö O, Völlit SE, Refsum H, Stemmer I, Tverdal A, Nord-
56. Cortese C, Motti C. MTHFR gene polymorphism, homocysteine 
55. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, 
54. Glass C, Pittman RC, Civen M, Steinberg D. Uptake of high-density lipoprotein-associated apoprotein A-1 and cho-
52. Tomas M, Sentí M, Gascón-Farías V, Vila J, Torrents A, Covas 
51. Jakubowski H. Translational accuracy of aminoacyl-tRNA syn-
48. Acton SL, Scherer PE, Lodish HF, Krieger M. Expression clo-
47. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, 
44. Acton SL, Scherer PE, Lodish HF, Krieger M. Expression clo-
43. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, 
40. Acton SL, Scherer PE, Lodish HF, Krieger M. Expression clo-
39. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, 
37. Starkbaum G, Harlan JM. Endothelial cell injury due to cop-
36. Ingvarsson T, Elmnur H, Steinberg D. Characterization of CLA-1, a human homologou-
35. Murao K, Terpstra V, Green SR, Kondratenko N, Steinberg D, Quehenberger O. Characterization of CLA-1: a human homologou-
34. Calvo D, Vega MA. Identification, primary structure, and distri-
33. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, 
30. Acton SL, Scherer PE, Lodish HF, Krieger M. Expression clo-
29. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, 
27. Starkbaum G, Harlan JM. Endothelial cell injury due to cop-
26. Ingvarsson T, Elmnur H, Steinberg D. Characterization of CLA-1, a human homologou-
25. Calvo D, Vega MA. Identification, primary structure, and distri-
24. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, 
22. Starkbaum G, Harlan JM. Endothelial cell injury due to cop-
21. Ingvarsson T, Elmnur H, Steinberg D. Characterization of CLA-1, a human homologou-
20. Calvo D, Vega MA. Identification, primary structure, and distri-
19. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, 
17. Starkbaum G, Harlan JM. Endothelial cell injury due to cop-
16. Ingvarsson T, Elmnur H, Steinberg D. Characterization of CLA-1, a human homologou-
15. Calvo D, Vega MA. Identification, primary structure, and distri-
14. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, 
12. Starkbaum G, Harlan JM. Endothelial cell injury due to cop-
11. Ingvarsson T, Elmnur H, Steinberg D. Characterization of CLA-1, a human homologou-
10. Calvo D, Vega MA. Identification, primary structure, and distri-
9. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, 
7. Starkbaum G, Harlan JM. Endothelial cell injury due to cop-
6. Ingvarsson T, Elmnur H, Steinberg D. Characterization of CLA-1, a human homologou-
5. Calvo D, Vega MA. Identification, primary structure, and distri-
4. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, 
2. Starkbaum G, Harlan JM. Endothelial cell injury due to cop-
1. Ingvarsson T, Elmnur H, Steinberg D. Characterization of CLA-1, a human homologou-

Rodríguez Esparragón F et al. Concerning the Significance of Paraoxonase-1 and SR-B1 Genes in Atherosclerosis

4. Weiss N, Heydrick SJ, Posta O, Keller C, Keaney JF Jr, Los-
calzo J. Influence of hyperhomocysteinemia on the cellular re-
4. Weiss N, Heydrick SJ, Posta O, Keller C, Keaney JF Jr, Los-
calzo J. Influence of hyperhomocysteinemia on the cellular re-
40:1000. Rev Esp Cardiol. 2006;59(2):154-64. 163